{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:51:30Z","timestamp":1790009490418,"version":"4.0.1"},"reference-count":182,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Flecainide acetate is a Class 1c anti-arrhythmic with a potent sodium voltage gated channel blockade which is utilized for the second-line treatment of tachyarrhythmias in children and adults. Given its narrow therapeutic index, the individualization of drug therapy is of utmost importance for clinicians. Despite efforts to improve anti-arrhythmic drug therapy, there remain knowledge gaps regarding the impact of variation in the genes relevant to flecainide\u2019s disposition and response. This variability is compounded in developing children whose drug disposition and response pathways may remain immature. The purpose of this comprehensive review is to outline flecainide\u2019s disposition and response pathways while simultaneously highlighting opportunities for prospective investigation in the pediatric population.<\/jats:p>","DOI":"10.3389\/fphar.2024.1477485","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T04:18:17Z","timestamp":1734322697000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric flecainide pharmacogenomics: a roadmap to delivering precision-based care to pediatrics arrhythmias"],"prefix":"10.3389","volume":"15","author":[{"given":"Ronald","family":"Palmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.yjmcc.2009.08.025","article-title":"Cardiac sodium channel Na(v)1.5 and interacting proteins: physiology and pathophysiology","volume":"48","author":"Abriel","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1136\/heart.89.10.1261","article-title":"Flecainide induced ventricular fibrillation in a neonate","volume":"89","author":"Ackland","year":"2003","journal-title":"Heart"},{"key":"B3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation","volume":"13","author":"Aliot","year":"2011","journal-title":"Europace"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/hrt.65.1.46","article-title":"Flecainide in the treatment of fetal tachycardias","volume":"65","author":"Allan","year":"1991","journal-title":"Br. Heart J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/01.res.83.2.141","article-title":"Novel LQT-3 mutation affects Na+ channel activity through interactions between alpha- and beta1-subunits","volume":"83","author":"An","year":"1998","journal-title":"Circ. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1124\/jpet.105.094615","article-title":"Genetic variants of the human dipeptide transporter PEPT1","volume":"316","author":"Anderle","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1056\/NEJM198108273050901","article-title":"Oral flecainide acetate for the treatment of ventricular arrhythmias","volume":"305","author":"Anderson","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/01.res.66.3.789","article-title":"Interactions of flecainide with Guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery","volume":"66","author":"Anno","year":"1990","journal-title":"Circ. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1021\/jm00152a021","article-title":"Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzam ide acetate, and antiarrhythmic properties of the enantiomers","volume":"29","author":"Banitt","year":"1986","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/bph.13521","article-title":"Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor","volume":"173","author":"Bannister","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/CIRCRESAHA.116.305347","article-title":"The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2","volume":"116","author":"Bannister","year":"2015","journal-title":"Circ. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.clpt.2004.08.021","article-title":"Bioequivalence revisited: influence of age and sex on CYP enzymes","volume":"76","author":"Bebia","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1161\/01.cir.101.14.1698","article-title":"Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?","volume":"101","author":"Benhorin","year":"2000","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/0002-9149(87)90915-5","article-title":"Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation","volume":"59","author":"Berns","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/FPC.0b013e32810f2e58","article-title":"Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues","volume":"17","author":"Bieche","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1203\/01.pdr.0000245909.74166.00","article-title":"Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants","volume":"60","author":"Blake","year":"2006","journal-title":"Pediatr. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/sj.clpt.6100101","article-title":"Ontogeny of dextromethorphan O- and N-demethylation in the first year of life","volume":"81","author":"Blake","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/106002809402800907","article-title":"Flecainide distribution, transplacental passage, and accumulation in the amniotic fluid during the third trimester of pregnancy","volume":"28","author":"Bourget","year":"1994","journal-title":"Ann. Pharmacother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijcard.2017.11.095","article-title":"Multifocal atrial and ventricular premature contractions with an increased risk of dilated cardiomyopathy caused by a Na(v)1.5 gain-of-function mutation (G213D)","volume":"257","author":"Calloe","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00543319","article-title":"The acute changes in serum binding of disopyramide and flecainide after myocardial infarction","volume":"28","author":"Caplin","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/clpt.1988.129","article-title":"Maturation of caffeine metabolic pathways in infancy","volume":"44","author":"Carrier","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/adc.61.7.657","article-title":"Serum albumin concentrations and oedema in the newborn","volume":"61","author":"Cartlidge","year":"1986","journal-title":"Arch. Dis. Child."},{"key":"B23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","article-title":"P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations","author":"Cascorbi","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0896-6273(00)81133-2","article-title":"From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels","volume":"26","author":"Catterall","year":"2000","journal-title":"Neuron"},{"key":"B25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2125.1994.tb05706.x","article-title":"Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults","volume":"37","author":"Cazeneuve","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2133\/dmpk.23.243","article-title":"Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences","volume":"23","author":"Choi","year":"2008","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B27","first-page":"643","article-title":"Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans","volume":"6","author":"Conard","year":"1984","journal-title":"Clin. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"41B","DOI":"10.1016\/0002-9149(84)90501-0","article-title":"Metabolism of flecainide","volume":"53","author":"Conard","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00228-004-0831-3","article-title":"Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation","volume":"60","author":"Deneer","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1905871","DOI":"10.1155\/2019\/1905871","article-title":"Cardiogenic shock in a hemodialyzed patient on flecainide: treatment with intravenous fat emulsion, extracorporeal cardiac life support, and CytoSorb\u00ae hemoadsorption","volume":"2019","author":"De Schryver","year":"2019","journal-title":"Case Rep. Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2125.2009.03435.x","article-title":"Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism","volume":"68","author":"Doki","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00228-007-0348-7","article-title":"Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia","volume":"63","author":"Doki","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00228-006-0188-x","article-title":"Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia","volume":"62","author":"Doki","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.dmpk.2015.04.001","article-title":"Serum flecainide S\/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity","volume":"30","author":"Doki","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"609733","DOI":"10.3389\/fphys.2020.609733","article-title":"Life cycle of the cardiac voltage-gated sodium channel Na(V)1.5","volume":"11","author":"Dong","year":"2020","journal-title":"Front. Physiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/14767058.2017.1286317","article-title":"Flecainide as first-line treatment for fetal supraventricular tachycardia","volume":"31","author":"Ekiz","year":"2018","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/0735-1097(91)90586-x","article-title":"Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group","volume":"18","author":"Fish","year":"1991","journal-title":"J. Am. Coll. Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1161\/01.cir.67.5.1117","article-title":"A multicenter clinical trial","volume":"67","year":"1983","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/01.cir.82.1.289","article-title":"Block of delayed rectifier potassium current, Ik, by flecainide and E-4031 in cat ventricular myocytes","volume":"82","author":"Follmer","year":"1990","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/cvr\/26.11.1121","article-title":"Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock","volume":"26","author":"Follmer","year":"1992","journal-title":"Cardiovasc Res."},{"key":"B42","first-page":"105","volume-title":"Food and drug modernization Act of 1997","year":"1997"},{"key":"B43","volume-title":"Specific requirements on content and format of labeling for human prescription drugs: revision of \u201cpediatric use\u201d subsection in the labelling: final rule (21 C.F.R. part 201)","year":"1994"},{"key":"B44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/j.1552-4604.1988.tb03142.x","article-title":"Oral flecainide pharmacokinetics in patients with impaired renal function","volume":"28","author":"Forland","year":"1988","journal-title":"J. Clin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1152\/physrev.1996.76.3.887","article-title":"Structure and function of voltage-dependent sodium channels: comparison of brain II and cardiac isoforms","volume":"76","author":"Fozzard","year":"1996","journal-title":"Physiol. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1248\/bpb.29.997","article-title":"The extracellular pH dependency of transport activity by human oligopeptide transporter 1 (hPEPT1) expressed stably in Chinese hamster ovary (CHO) cells: a reason for the bell-shaped activity versus pH","volume":"29","author":"Fujisawa","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"B47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/clpt.1994.26","article-title":"Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone","volume":"55","author":"Funck-Brentano","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.pcl.2012.07.003","article-title":"Pediatric pharmacokinetics: human development and drug disposition","volume":"59","author":"Funk","year":"2012","journal-title":"Pediatr. Clin. North Am."},{"key":"B49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/s0022-3476(81)80578-1","article-title":"Supraventricular tachycardia in children: clinical features, response to treatment, and long-term follow-up in 217 patients","volume":"98","author":"Garson","year":"1981","journal-title":"J. Pediatr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/CIRCEP.108.789081","article-title":"Cardiac ion channels","volume":"2","author":"Grant","year":"2009","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1002\/jcph.1853","article-title":"Methods used for pediatric dose selection in drug development programs submitted to the US FDA 2012-2020","volume":"61","author":"Green","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-2125.1989.tb03542.x","article-title":"Stereoselective disposition of flecainide in relation to the sparteine\/debrisoquine metaboliser phenotype","volume":"28","author":"Gross","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/CIRCULATIONAHA.105.586107","article-title":"Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5)","volume":"113","author":"Grube","year":"2006","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0006-2952(94)90223-2","article-title":"Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver","volume":"48","author":"Hakkola","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1345\/aph.1C487","article-title":"Neonatal flecainide toxicity following supraventricular tachycardia treatment","volume":"37","author":"Hall","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1113\/jphysiol.2004.079681","article-title":"Expression pattern of neuronal and skeletal muscle voltage-gated Na+ channels in the developing mouse heart","volume":"564","author":"Haufe","year":"2005","journal-title":"J. Physiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/jbt.20179","article-title":"Ontogeny of human hepatic cytochromes P450","volume":"21","author":"Hines","year":"2007","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pharmthera.2008.02.005","article-title":"The ontogeny of drug metabolism enzymes and implications for adverse drug events","volume":"118","author":"Hines","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1124\/jpet.300.2.355","article-title":"The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes","volume":"300","author":"Hines","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","article-title":"Transporters and drug therapy: implications for drug disposition and disease","volume":"78","author":"Ho","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00005344-197907000-00005","article-title":"Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart","volume":"1","author":"Hodess","year":"1979","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-198529010-00001","article-title":"Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy","volume":"29","author":"Holmes","year":"1985","journal-title":"Drugs"},{"key":"B63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1211\/0022357055128","article-title":"Assessment of serum flecainide trough levels in patients with tachyarrhythmia","volume":"57","author":"Homma","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/bdd.1877","article-title":"Pharmacokinetic variability of flecainide in younger Japanese patients and mechanisms for renal excretion and intestinal absorption","volume":"35","author":"Horie","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"B65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1515\/dmdi-2011-0032","article-title":"Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects","volume":"27","author":"Hu","year":"2012","journal-title":"Drug Metabol. Drug Interact."},{"key":"B66","doi-asserted-by":"publisher","first-page":"17B","DOI":"10.1016\/0002-9149(84)90495-8","article-title":"Discovery and development of flecainide","volume":"53","author":"Hudak","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0735-1097(85)80051-6","article-title":"Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers","volume":"5","author":"Ikeda","year":"1985","journal-title":"J. Am. Coll. Cardiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jemermed.2012.07.050","article-title":"A case of near-fatal flecainide overdose in a neonate successfully treated with sodium bicarbonate","volume":"44","author":"Jang","year":"2013","journal-title":"J. Emerg. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cell.2019.11.041","article-title":"Structure of the cardiac sodium channel","volume":"180","author":"Jiang","year":"2020","journal-title":"Cell."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.103.053298","article-title":"Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3)","volume":"308","author":"Jonker","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/clinchem\/41.4.605","article-title":"Serum concentrations of 10 acute-phase proteins in healthy term and preterm infants from birth to age 6 months","volume":"41","author":"Kanakoudi","year":"1995","journal-title":"Clin. Chem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/apc.APC_31_17","article-title":"Flecainide toxicity in a preterm neonate with permanent junctional reciprocating tachycardia","volume":"10","author":"Karmegaraj","year":"2017","journal-title":"Ann. Pediatr. Cardiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","article-title":"Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy","author":"Keppler","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/clpt.2008.25","article-title":"ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin","volume":"84","author":"Keskitalo","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03188723","article-title":"Clinical pharmacokinetics of atenolol--a review","volume":"7","author":"Kirch","year":"1982","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1124\/jpet.103.060137","article-title":"Developmental expression of human hepatic CYP2C9 and CYP2C19","volume":"308","author":"Koukouritaki","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1161\/CIRCRESAHA.120.316819","article-title":"RYR2 channel inhibition is the principal mechanism of flecainide action in CPVT","volume":"128","author":"Kryshtal","year":"2021","journal-title":"Circ. Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"22B","DOI":"10.1016\/0002-9149(84)90497-1","article-title":"Antiarrhythmic and electrophysiologic actions of flecainide in animal models","volume":"53","author":"Kvam","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40272-019-00352-8","article-title":"Drug dose selection in pediatric obesity: available information for the most commonly prescribed drugs to children","volume":"21","author":"Kyler","year":"2019","journal-title":"Paediatr. Drugs"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/0006-2952(91)90244-y","article-title":"Human embryonic cytochrome P450S: phenoxazone ethers as probes for expression of functional isoforms during organogenesis","volume":"42","author":"Lee","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/sj.tpj.6500104","article-title":"The challenges of delivering pharmacogenomics into clinical pediatrics","volume":"2","author":"Leeder","year":"2002","journal-title":"Pharmacogenomics J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2012.130","article-title":"Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target","volume":"92","author":"Leeder","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/0091270009360533","article-title":"Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science","volume":"50","author":"Leeder","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1517\/phgs.4.3.331.22693","article-title":"Developmental and pediatric pharmacogenomics","volume":"4","author":"Leeder","year":"2003","journal-title":"Pharmacogenomics"},{"key":"B88","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1542\/peds.79.2.264","article-title":"Delay in caffeine elimination in breast-fed infants","volume":"79","author":"Le Guennec","year":"1987","journal-title":"Pediatrics"},{"key":"B89","doi-asserted-by":"publisher","first-page":"ytab158","DOI":"10.1093\/ehjcr\/ytab158","article-title":"You cannot ablate the Lernaean Hydra: SCN5A mutation in a patient with multifocal ectopic Purkinje-related premature contractions syndrome treated with Flecainide and an implant of a subcutaneous defibrillator-a case report","volume":"5","author":"Leventopoulos","year":"2021","journal-title":"Eur. Heart J. Case Rep."},{"key":"B90","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1074\/jbc.270.12.6456","article-title":"Human intestinal H+\/peptide cotransporter. Cloning, functional expression, and chromosomal localization","volume":"270","author":"Liang","year":"1995","journal-title":"J. Biol. Chem."},{"key":"B91","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1365-2125.2008.03267.x","article-title":"Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects","volume":"66","author":"Lim","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.clinthera.2010.04.002","article-title":"Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects","volume":"32","author":"Lim","year":"2010","journal-title":"Clin. Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1161\/01.RES.0000235869.50747.e1","article-title":"Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model","volume":"99","author":"Liu","year":"2006","journal-title":"Circ. Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/CIRCRESAHA.111.247338","article-title":"Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity","volume":"109","author":"Liu","year":"2011","journal-title":"Circ. Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1053\/cp.1999.v66.103400001","article-title":"Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"66","author":"Luzier","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/bod.2510090602","article-title":"The potential role of lysosomes in tissue distribution of weak bases","volume":"9","author":"MacIntyre","year":"1988","journal-title":"Biopharm. Drug Dispos."},{"key":"B97","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/2150135113481042","article-title":"Off-label drug use in a single-center pediatric cardiac intensive care unit","volume":"4","author":"Maltz","year":"2013","journal-title":"World J. Pediatr. Congenit. Heart Surg."},{"key":"B98","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1152\/physrev.1996.76.3.631","article-title":"Cellular functions of immunophilins","volume":"76","author":"Marks","year":"1996","journal-title":"Physiol. Rev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"100948","DOI":"10.1016\/j.margen.2022.100948","article-title":"Regulation of gene expression during ontogeny of physiological function in the brackishwater amphipod Gammarus chevreuxi","volume":"63","author":"McAndry","year":"2022","journal-title":"Mar. Genomics"},{"key":"B100","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/FJC.0b013e3181abc288","article-title":"The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel","volume":"54","author":"McBride","year":"2009","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1124\/jpet.300.2.361","article-title":"The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms","volume":"300","author":"McCarver","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/cts.12607","article-title":"Considerations for implementing precision therapeutics for children","volume":"12","author":"McLaughlin","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/clpt.1988.195","article-title":"Pharmacokinetics of flecainide in patients with cirrhosis of the liver","volume":"44","author":"McQuinn","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"B104","first-page":"414","article-title":"Biotransformation and elimination of 14C-flecainide acetate in humans","volume":"12","author":"McQuinn","year":"1984","journal-title":"Drug Metab. Dispos."},{"key":"B105","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/clpt.1989.73","article-title":"The influence of the sparteine\/debrisoquin phenotype on the disposition of flecainide","volume":"45","author":"Mikus","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jacc.2019.06.024","article-title":"Antenatal therapy for fetal supraventricular tachyarrhythmias: multicenter trial","volume":"74","author":"Miyoshi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00246-014-0978-3","article-title":"Flecainide use in children with cardiomyopathy or structural heart disease","volume":"36","author":"Moffett","year":"2015","journal-title":"Pediatr. Cardiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/00005344-198912000-00018","article-title":"Effect of altered repolarization course induced by antiarrhythmic drugs and constant current pulses on duration of premature action potentials in canine cardiac Purkinje fibers","volume":"14","author":"Nakaya","year":"1989","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-2125.1984.tb05006.x","article-title":"Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels","volume":"17","author":"Nau","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-3-642-14541-4_3","article-title":"Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy","author":"Nies","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd4461","article-title":"What do drug transporters really do?","volume":"14","author":"Nigam","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B112","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/0002-8703(81)90037-5","article-title":"Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation","volume":"102","author":"Olsson","year":"1981","journal-title":"Am. Heart J."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/europace\/euac218","article-title":"Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide","volume":"25","author":"O'Reilly","year":"2023","journal-title":"Europace"},{"key":"B114","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2125.2000.00128.x","article-title":"Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population","volume":"49","author":"Ou-Yang","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/clpt.1993.9","article-title":"Pharmacodynamic variability of flecainide assessed by QRS changes","volume":"53","author":"Padrini","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1168619","DOI":"10.3389\/fped.2023.1168619","article-title":"Case report: use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia","volume":"11","author":"Palmen","year":"2023","journal-title":"Front. Pediatr."},{"key":"B117","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCOUTCOMES.108.787176","article-title":"Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease","volume":"1","author":"Pasquali","year":"2008","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/0002-8703(92)90081-6","article-title":"Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing","volume":"124","author":"Perry","year":"1992","journal-title":"Am. Heart J."},{"key":"B119","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0735-1097(89)90070-3","article-title":"Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics","volume":"14","author":"Perry","year":"1989","journal-title":"J. Am. Coll. Cardiol."},{"key":"B120","unstructured":"PharmGKB API2024"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e20192608","DOI":"10.1542\/peds.2019-2608","article-title":"Complete heart block secondary to flecainide toxicity: is it time for CYP2D6 genotype testing?","volume":"146","author":"Poh","year":"2020","journal-title":"Pediatrics"},{"key":"B122","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1074\/jbc.275.8.5997","article-title":"Expression of distinct ERG proteins in rat, mouse, and human heart. Relation to functional I(Kr) channels","volume":"275","author":"Pond","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B123","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cpt.409","article-title":"Ontogeny of hepatic drug transporters as quantified by LC-MS\/MS proteomics","volume":"100","author":"Prasad","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B124","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.cir.0000020013.73106.d8","article-title":"Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia","volume":"106","author":"Priori","year":"2002","journal-title":"Circulation"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1161\/01.cir.0000019513.50928.74","article-title":"Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block","volume":"105","author":"Rajamani","year":"2002","journal-title":"Circulation"},{"key":"B126","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/s0022-3476(71)80369-4","article-title":"Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants","volume":"78","author":"Rane","year":"1971","journal-title":"J. Pediatr."},{"key":"B127","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.physiol.64.083101.145105","article-title":"Cardiac ion channels","volume":"64","author":"Roden","year":"2002","journal-title":"Annu. Rev. Physiol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1542\/peds.2007-1529","article-title":"Improving pediatric dosing through pediatric initiatives: what we have learned","volume":"121","author":"Rodriguez","year":"2008","journal-title":"Pediatrics"},{"key":"B129","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s0379-0738(99)00156-5","article-title":"Fatal flecainide intoxication","volume":"106","author":"Romain","year":"1999","journal-title":"Forensic Sci. Int."},{"key":"B130","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/adc.64.6.860","article-title":"Flecainide toxicity","volume":"64","author":"Russell","year":"1989","journal-title":"Arch. Dis. Child."},{"key":"B131","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/clpt.1986.145","article-title":"Pharmacodynamics and side effects of flecainide acetate","volume":"40","author":"Salerno","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/cells10082101","article-title":"Flecainide paradoxically activates cardiac ryanodine receptor channels under low activity conditions: a potential pro-arrhythmic action","volume":"10","author":"Salvage","year":"2021","journal-title":"Cells"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e202213089","DOI":"10.1085\/jgp.202213089","article-title":"How does flecainide impact RyR2 channel function?","volume":"154","author":"Salvage","year":"2022","journal-title":"J. Gen. Physiol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1152\/physrev.00022.2013","article-title":"Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia","volume":"94","author":"Schmitt","year":"2014","journal-title":"Physiol. Rev."},{"key":"B135","first-page":"524","article-title":"Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)","volume":"70","author":"Seipel","year":"1981","journal-title":"Z Kardiol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00246-012-0474-6","article-title":"A multi-institutional analysis of inpatient treatment for supraventricular tachycardia in newborns and infants","volume":"34","author":"Seslar","year":"2013","journal-title":"Pediatr. Cardiol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/cvr\/cvt012","article-title":"Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current","volume":"98","author":"Sikkel","year":"2013","journal-title":"Cardiovasc Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/BF00168654","article-title":"Electrophysiological effects of flecainide enantiomers in canine Purkinje fibres","volume":"339","author":"Smallwood","year":"1989","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/0002-8703(87)90301-2","article-title":"Chronic flecainide therapy selected by electrophysiology testing of intravenous flecainide","volume":"114","author":"Somberg","year":"1987","journal-title":"Am. Heart J."},{"key":"B140","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2165\/00003088-198712050-00002","article-title":"Pharmacokinetic interactions of cimetidine 1987","volume":"12","author":"Somogyi","year":"1987","journal-title":"Clin. Pharmacokinet."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1080\/00498250802130039","article-title":"Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes","volume":"38","author":"Song","year":"2008","journal-title":"Xenobiotica"},{"key":"B142","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1046\/j.1432-1327.1998.2510893.x","article-title":"Delayed ontogenesis of CYP1A2 in the human liver","volume":"251","author":"Sonnier","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1161\/01.cir.102.10.1178","article-title":"Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2","volume":"102","author":"Splawski","year":"2000","journal-title":"Circulation"},{"key":"B144","doi-asserted-by":"publisher","first-page":"euad156","DOI":"10.1093\/europace\/euad156","article-title":"RYR2-ryanodinopathies: from calcium overload to calcium deficiency","volume":"25","author":"Steinberg","year":"2023","journal-title":"Europace"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/NEJMhpr021646","article-title":"Testing medications in children","volume":"347","author":"Steinbrook","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1124\/dmd.108.021873","article-title":"Developmental changes in human liver CYP2D6 expression","volume":"36","author":"Stevens","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"B147","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamapediatrics.2013.4604","article-title":"Newborns, one of the last therapeutic orphans to be adopted","volume":"168","author":"Stiers","year":"2014","journal-title":"JAMA Pediatr."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.hrthm.2016.01.029","article-title":"High-dose flecainide is the most effective treatment of fetal supraventricular tachycardia","volume":"13","author":"Strizek","year":"2016","journal-title":"Heart rhythm."},{"key":"B149","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cardiores.2003.12.026","article-title":"Pharmacology of cardiac potassium channels","volume":"62","author":"Tamargo","year":"2004","journal-title":"Cardiovasc Res."},{"key":"B150","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jacep.2021.10.004","article-title":"Arrhythmias in pregnancy","volume":"8","author":"Tamirisa","year":"2022","journal-title":"JACC Clin. Electrophysiol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1067\/mcp.2002.125946","article-title":"Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism","volume":"72","author":"Tenneze","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.hrcr.2018.05.010","article-title":"Beauty and the beat: a complicated case of multifocal ectopic Purkinje-related premature contractions","volume":"4","author":"Ter Bekke","year":"2018","journal-title":"Hear. Case Rep."},{"key":"B153","doi-asserted-by":"publisher","first-page":"bcr0220125810","DOI":"10.1136\/bcr.02.2012.5810","article-title":"Decreased milk drinking causing flecainide toxicity in an older child","volume":"2012","author":"Thompson","year":"2012","journal-title":"BMJ Case Rep."},{"key":"B154","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/adc.62.3.247","article-title":"Treatment of refractory supraventricular arrhythmias with flecainide acetate","volume":"62","author":"Till","year":"1987","journal-title":"Arch. Dis. Child."},{"key":"B155","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/hrt.62.2.133","article-title":"Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics","volume":"62","author":"Till","year":"1989","journal-title":"Br. Heart J."},{"key":"B156","first-page":"108","article-title":"Altered pharmacokinetics of oral flecainide by cimetidine","volume":"22","author":"Tjandra-Maga","year":"","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1365-2125.1986.tb02892.x","article-title":"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man","volume":"22","author":"Tjandra-Maga","year":"","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1432-1033.1991.tb16411.x","article-title":"Expression of CYP2D6 in developing human liver","volume":"202","author":"Treluyer","year":"1991","journal-title":"Eur. J. Biochem."},{"key":"B159","first-page":"64","article-title":"Supraventricular tachycardia in children","volume":"15","author":"Van der Merwe","year":"2004","journal-title":"Cardiovasc J. S Afr."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/ehf2.14677","article-title":"Novel SCN5A gene mutation in a patient affected by multifocal ectopic premature Purkinje-related contractions syndrome","volume":"11","author":"Ventrella","year":"2024","journal-title":"Esc. Heart Fail"},{"key":"B161","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2459\/01.JCM.0000247438.12817.9e","article-title":"Pediatric arrhythmias: which are the news?","volume":"8","author":"Vignati","year":"2007","journal-title":"J. Cardiovasc Med. Hagerst."},{"key":"B162","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1542\/pir.34-6-258","article-title":"Pediatric pharmacokinetics","volume":"34","author":"Wagner","year":"2013","journal-title":"Pediatr. Rev."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.pcl.2012.07.008","article-title":"Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children","volume":"59","author":"Wagner","year":"2012","journal-title":"Pediatr. Clin. North Am."},{"key":"B164","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/genes15030379","article-title":"Pediatric beta blocker therapy: a comprehensive review of development and genetic variation to guide precision-based therapy in children, adolescents, and young adults","volume":"15","author":"Walton","year":"2024","journal-title":"Genes. (Basel)"},{"key":"B165","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/FPC.0b013e328302cd41","article-title":"OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine","volume":"18","author":"Wang","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"B166","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40272-014-0099-8","article-title":"Ethics of drug studies in the newborn","volume":"17","author":"Ward","year":"2015","journal-title":"Paediatr. Drugs"},{"key":"B167","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat. Med."},{"key":"B168","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.hrthm.2012.12.035","article-title":"Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia","volume":"10","author":"Watanabe","year":"2013","journal-title":"Heart rhythm."},{"key":"B169","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/s0002-8703(96)90052-6","article-title":"Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants","volume":"131","author":"Weindling","year":"1996","journal-title":"Am. Heart J."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1542\/peds.2013-2987","article-title":"Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy","volume":"134","author":"Wharton","year":"2014","journal-title":"Pediatrics"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"B172","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF00560385","article-title":"The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding","volume":"7","author":"Windorfer","year":"1974","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1113\/JP276757","article-title":"Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia","volume":"598","author":"Wleklinski","year":"2020","journal-title":"J. Physiol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00246-005-1126-x","article-title":"Medications used to manage supraventricular tachycardia in the infant a North American survey","volume":"27","author":"Wong","year":"2006","journal-title":"Pediatr. Cardiol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/hrt.57.2.171","article-title":"The response of paediatric arrhythmias to intravenous and oral flecainide","volume":"57","author":"Wren","year":"1987","journal-title":"Br. Heart J."},{"key":"B176","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/0006-2952(94)00493-6","article-title":"Expression of functional cytochrome P4501A1 in human embryonic hepatic tissues during organogenesis","volume":"49","author":"Yang","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1358\/mf.2002.24.2.677131","article-title":"Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model","volume":"24","author":"Yokogawa","year":"2002","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/0002-9149(88)91232-5","article-title":"Flecainide for supraventricular and ventricular arrhythmias in children and young adults","volume":"62","author":"Zeigler","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"21061","DOI":"10.1074\/jbc.273.33.21061","article-title":"HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects","volume":"273","author":"Zhou","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B180","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00210-008-0369-5","article-title":"Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2)","volume":"379","author":"Zolk","year":"2009","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/phrs.1993.1129","article-title":"Influence of age and gender on the in vitro serum protein binding of flecainide","volume":"28","author":"Zordan","year":"1993","journal-title":"Pharmacol. Res."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3382\/ps.2012-02826","article-title":"Expression of the peptide transporters PepT1, PepT2, and PHT1 in the embryonic and posthatch chick","volume":"92","author":"Zwarycz","year":"2013","journal-title":"Poult. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1477485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T04:18:29Z","timestamp":1734322709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1477485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":182,"alternative-id":["10.3389\/fphar.2024.1477485"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1477485","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1477485"}}